EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Coexistence of lymphoplasmacytic lymphoma and multiple myeloma: a case report and review of literature

Xiao-Qin Yang, Ting-Ting Liu, Hai-Yun Liu, Liang Li

Frontiers in Oncology · 26.06.2026 · 16

DOI: 10.3389/fonc.2026.1789073 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 26.06.2026. Verfasst von Xiao-Qin Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Jinxi County Hospital of Traditional Chinese Medicine, Fuzhou, China. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymphoplasmacytic lymphoma (LPL) and multiple myeloma (MM) are distinct B−cell neoplasms whose synchronous occurrence is extremely rare. We report a case of a 68−year−old man presenting with fatigue and bone pain. Laboratory studies showed hyperglobulinemia (71.1 g/L), severe normocytic anemia (hemoglobin 44 g/L, MCV 79.5 fL), and thrombocytopenia. Serum immunofixation revealed dual IgG−kappa and IgM−kappa monoclonal proteins. Imaging showed diffuse osteolytic lesions in the skull and spine. Bone marrow flow cytometry identified two immunophenotypically distinct populations: CD19+/CD20+/CD5-/CD10- B−cells (34.1%) and CD138+/CD38+/cytoplasmic kappa+ plasma cells (4.5%). Next−generation sequencing on unsorted whole bone marrow detected MYD88 c.779T>C (p.Leu260Pro, canonical L265P) with a variant allele frequency (VAF) of 40.00% and CXCR4 c.1013C>G (p.Ser338*) nonsense mutation with VAF 15.53%, confirming LPL. Although the clonal plasma cell percentage was below the traditional 10% threshold, the presence of unequivocal osteolytic lesions and severe anemia (CRAB criteria) supported a diagnosis of active MM. The patient was treated with zanubrutinib, bortezomib, and dexamethasone, achieving a partial response. This case strongly suggests that LPL and MM can coexist, but definitive proof of biclonality would require sorted−cell molecular studies. We highlight the diagnostic challenges and the importance of integrating clinical, immunophenotypic, and molecular data.

Schlagwörter

Stichwörter der Autor:innen

MYD88 L265PWaldenström’s macroglobulinemialymphoplasmacytic lymphomamultiple myelomazanubrutinib

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Jinxi County Hospital of Traditional Chinese Medicine, Fuzhou, China.
  • Department of Hematology, Jiangxi Provincial People's Hospital / The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
  • Department of Laboratory Medicine, Jiangxi Provincial People's Hospital / The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.

Zitieren

APA

Yang, X. Q., Liu, T. T., Liu, H. Y., & Li, L. (2026). Coexistence of lymphoplasmacytic lymphoma and multiple myeloma: a case report and review of literature. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1789073

Vancouver

Yang XQ, Liu TT, Liu HY, Li L. Coexistence of lymphoplasmacytic lymphoma and multiple myeloma: a case report and review of literature. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1789073

BibTeX
@article{Yang2026,
  author = {Yang, Xiao-Qin and Liu, Ting-Ting and Liu, Hai-Yun and Li, Liang},
  title = {Coexistence of lymphoplasmacytic lymphoma and multiple myeloma: a case report and review of literature},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1789073}
}
Kostenlos starten →